No products in the cart.

Chapter 10. Pharmacogenomics

Pharmacotherapeutics for Advanced Practice 3rd Edition by Virginia Poole Arcangelo, Andrew M. Peterson

$2.99

Chapter 10. Pharmacogenomics

 

Complete Chapter Questions With Answers

 

Sample Questions Are Posted Below

 

MULTIPLE CHOICE

 

  1. Genetic polymorphisms account for differences in metabolism, including:
A. Poor metabolizers (PMs) who lack a working enzyme
B. Intermediate metabolizers (IMs) who have one working, wild-type allele and one mutant allele
C. Extensive metabolizers (EMs), with two normally functioning alleles
D. All of the above

 

 

ANS:  D                    PTS:   1

 

  1. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
A. A need to monitor drugs metabolized by 2D6 for toxicity
B. Increased dosages needed of drugs metabolized by 2D6, such as the SSRIs
C. Decreased conversion of codeine to morphine by CYP 2D6
D. The need for lowered dosages of drugs, such as beta blockers

 

 

ANS:  B                    PTS:   1

 

  1. Rifampin is a nonspecific CYP450 inducer that may:
A. Lead to toxic levels of rifampin and must be monitored closely
B. Cause toxic levels of drugs, such as oral contraceptives, when co-administered
C. Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic failure
D. Cause nonspecific changes in drug metabolism

 

 

ANS:  C                    PTS:   1

 

  1. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
A. Decreased therapeutic levels of quinidine
B. Increased therapeutic levels of quinidine
C. Decreased levels of a co-administered drug, such as digoxin, that requires P-glycoprotein for absorption and elimination
D. Increased levels of a co-administered drug, such as digoxin, that requires P-glycoprotein for absorption and elimination

 

 

ANS:  D                    PTS:   1

Additional information

Add Review

Your email address will not be published. Required fields are marked *